Natural killer cell infusion for advanced solid tumors
Treatments studied
This trial tests an investigational natural killer (NK) cell therapy for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if these immune cells can shrink tumors and are safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- You must have an advanced solid tumor (a cancer that has spread or is hard to treat) that hasn't gotten better with standard treatments, or no standard treatment exists.
- You need at least one tumor that can be measured on a scan (about 1 cm or bigger).
- You should be in fairly good health overall (able to do light activity and care for yourself).
- Your heart, liver, kidneys, and blood counts must be within acceptable limits — the trial will check this with tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
This study tests a new immune cell treatment called EB-NK-301, which are lab-modified natural killer cells designed to attack cancer cells that have a protein called TROP2. The trial is for people with advanced solid tumors (cancers that have spread) whose cancer has stopped responding to standard treatments.
This early-stage trial tests NK521, a new immunotherapy infusion, for patients with advanced solid tumors (like liver, stomach, or colon cancer) that have spread and caused fluid buildup in the belly. The goal is to see if NK521 can help shrink tumors and improve survival when standard treatments have stopped working.
This Phase 1/2 study tests an intravenous (IV) immune-cell therapy made from donors (allogeneic NK cells) to treat advanced solid tumors, relapsed/refractory non-Hodgkin lymphoma, or multiple myeloma. It may help by targeting cancer cells more directly, but early-phase trials mainly focus on safety and finding the right dosing.
This trial tests whether adding special immune cells (iNKT cells and CD8+ T cells) given by IV infusion can help treat advanced cancers. It mainly looks at safety first, and also checks whether the treatment can shrink or control cancer.
This early-stage trial tests a new type of immune cell therapy (NK cells boosted with a protein called IL-15) to treat solid cancers that have spread or come back after standard treatment. The goal is to see if this approach can help shrink tumors and improve survival.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.